2025-08-31-accounts

DooJw9n Envelope ID. BaDeQ)2>a02E-8481-8221-030134A11A01 COMPANY REGISTIiATION NUMBER: 06400879 CHAii¥fY REGISTRATION NUMBER: 1122071 The Lily Foundation Company Limited by Guarantee Financial Statements 31 August 2025 111 AF2C¥P51 A11

181

COMPANIES HOUSE

Docusign En%*lwe ID.. 88oe002>802E4481.82214)30134A11A01 The Lily Foundation Company Limited by Guarantee Trustees. Annual Report (Incorporating the Directorfs Report) Year ended 31 August 2025 Thi5 Past year has marked signrfitant progress for the mrtochondrial disease communrty. From scientrfic breakthroughs to the tireless efforts of families. researchers and supporters across the UK, I feel immense pride in what we have achieved together and renewed hope for the future. It has beèn a remarkable period for research. We saw the success of mitochondrial donation IVF. a cause The Lity Foundation championed for many years, alon8Stde the approval of the first ever treatment for one form of mrtochondrial drsease. We also celebrated the launch of the £7.5 million LifeArc Cenire for Rare Mr(ochondrial Diseases. as well as new initiatwes including our IMPACT Patient Advisory Cornmtttee and the Lity Research Zone. boih designed to Slrenyhen the role of patients in shaping research and improvin8 access to information. Looking ahe3d, we remain committed to a¢fvaft¢ing research and ensuring that patieftt voices are centr31 to the future of mttochondri31 medicine. Recruitment to the Lity Precision Medicine Diagnostic Project will continue across specialist centres in the UK. helping to return dia8n05es to patient5 while strengthening NH5 genomic services. Plans for the UK Mitothondrial Disease Research Instituie will also continue to develop alongside our ongoing support for existing research studies. Support for families remains at the heart of everything we do. Our Adult Support Weekend has now become a valued fixture alongside our Famity and Young Adult events, and we continue to provide both ernotional and prattical sUPPOrt through initiatives such as online coun5ellin& virtU31 coffee mornings and peer-support netwoiks. Over the coming year we will also expand the distribution of our Lily patient information packs to help ensure farnilie5 receive clear and con515tent information at the point of diagnosis. Our patient-led work will continue to Brow. with IMPA￿ helpin8 to shape research. clinic31 tria15 and policy discu55ions. while the next phase of the Experience of Diagn051S Study will help us advocate for bmprovements in how mitochondrial diagnoses are delivered and 5UPPOrted. None of this work would be possible without our incredible supporters. To everyone who has run. walked. baked. boxed. danced. donated. volunteered or organised a Lily event. thank you. Your energy and generosity rnake everything we do p055ible and brin8 hope to famtslie5 affected by mitochondrial disease. As we look ahead. we will continue to strengthen and diversfy our fundraising to ensure The Lily Foundation remain5 5LlStainable and able to supwrt rts long-term ambitions in research, patient 5UPPOrt and advocacy. Liz Curtis Founder and Chief Executive Offiter

Docusi9n Enl¢we ID.. 88D8002>802E44814f214J30134A11A01 The Lily Foundation Company Llmfted by Guarantee Trustee5' Annual Report (Incorporating the DireGto¢s Report) (¢onltnv¢¢l Year ended 31 August 2025 2025 has been a strong and important year lor The Lity Foundation- one in which we have focused not only on delivering for the mr(ochondrial disease cornmunity today. but also on building the foundations for the future. From the 8oard's perspertive. one of the most signrficani achvements of the year has been the progress made in strengthening the charity's financral posit￿￿ and oversight. In a challenging climate for many charitie5, Lily has worked hard to improve transparency and financial scrutiny, and make careful. disciplined decisions about Pr￿TitieS and tnvestment. That approach has helped us end the year in a stronger positN)n. with income recovering well on the previous year and the charty better placed for the future. Alongside this. the organisatioft has continued to play at) influential role across the mitochondrial disease landscape. While the decision was taken to pause the research call during the year. this was the right and responsible slep at that point in time. Importantty. it did not dirninish Lily's wider contribution to research and patient engagement. Our team has continued to strèngthen relationships with leading clintcians. researchers and specialist ￿ntre$. and has represented LI￿ on the international research stage. The charrty has also played a key role in the delNery of the LifeArc pro8ramme- regular￿ cited by LrfeArc as'best in class. when rt comes io patient engagement. Perhaps most excrtingly, 2025 has also marked the early development of an ambrtious new vision.. the UK Mitochondrial Oisease Research Institute. This has the potential to be a maior step forward not only for Lity, but for the wider mitochondrial disease community. The strong support already shown by senior medical leaders is encouraging and reflects the credibilrty and ielationships the charity has built over many years. At the Same time, the Board bs clear that realising thi5 V15ion will require significant thought, planning and support. Delivering an initiative of ihis scale will call for new partnerships, drfferent capabilities. strong governance and substantial fundraising. tt represents a bold next ¢hapier for Lily, and one that we must approach with both ambition and care. I would like to thank Li2 for her leadership, and the wider Lify team fortheir commitment. skill and determination throughout the year. l am continualty struck by the energy. creativrty and resilience across the organisation. and by how much they achieve. My thanks also go to my fellow Tfustees for their support and contribution over the past year, partKularfy as we conttnue to strengthen the charitls Eovernance and committee strurture in sUPPOrt of its future ambitions. The LI￿ Foundation has never siood still. and 2025 has shown both the strength of what the charity already is and the scale of whai it could become. I look forward to the year ahead with confidence and with a strong sense of respon5ibilrty to the community we serve. Ben Carter Chair of Trustees

Oocusign Erwebpe ID.. B608ib)2>802E-84BI-8221-030134A11NI)1 The Lily Foundation Company Limited by Guarantee Trustees. Annual Report (Incorporating the Dlrectorfs Report) {c0J￿nua￿J Year ended 31 August 2025 The trustees. who are also the directors for the Pufposes of company law. present their report and the financial statements of the chartty for ihe year ended 31 August 2025. A summary of the objectives of the charity as set In Its go¥ernln8 documenL l - To prornote the physical and mental hea￿h of sufferers of mitochondrial disease and other metabolic disorders through greater aw4￿Me$S and funding. Activities undertaken to achieve this include provtsion of telephone helpltne. email support. closed patient support groups. virtual coffee mornings. social networkin& website and printed resources, patient crisis funding, provision of specialisi equipment, family breaks, residential weekends, patient information days. benefits advice and mental heahh support. Five members of staff Work in this area, and we have invested £2.419￿11 in this area to date12024.- £2,1)45.7401. 2 - To provide fund5 for further research into the disease. Activities undertaken to achieve this include mitochondrial exome sequencing program. peer reviewed research call for treatments for mitochondrial disease. funding of UK research studentships. research fellows, a Precision Diagnostic Research Project and the UK Mitochondrial Disease Research Institute. Participation In glob31 research collaborations. Three members of staff work in coordinating this area and we have invested £4.641.526 in this a￿a to date12024: £4,478,787). 3 - To provide greater aWa￿nesS to the public of mitochondrial disèase. Activitie5 undertakert to achteve this include public speakin& press and media campaigns. SL)tial media presence. NHS website providing reliable disease inforrnation. school visits. conference attendance. professional training and information ¥ideos. Six members of staff work in cwrdinating this area and we have invested £1,378.379 in this area to date12024.. £1.175.7851. Publi< Benefit that is provided by the chwlty l - To supM)rt families affected by rnito¢hondrial disease. 2 - To fund research which will improve accurary of diagn05i5 and treatrnent option5 for sufferer5 of mitochondrial disease. 3- To educate and raise awareness of mitochondrial disease to the public and the medical community. to increase recognition of these conditions. We have referred to the Charity Commission's guidan￿ on public benefit when reviewing our aims and objecttves and in planning our future activrties.

th>cuwgn Envelope ID". B8D8W2>802E.84B1-8221-o￿1)4A11A0l The Lily Foundation Company Limited by Guarantee Trustees. Annual Report (Incorporating the Directorfs Report) Year ended 31 August 2025 Contrlbution of volunteers The charity relies on voluntary help to host fvndrai%ing events, patient residential weekends and information days. Around 30 volunteers regularly assist the charity at events. helping reduce cost5. The Lity Foundation supports anyone in ihe UK who is affected by mitochondrial disease. We exist to ensvre every patient has a voice and access to t￿atMent. support to improve therr life and, ultimately. a Cu￿. We are working towards this vision in five key ways.. l. Pfoviding support to patients and families affected by mito- reducing isolation. tsJildin8 resilience and improvtng wellbeing. 2. Funding ground-breaking research to improve the accuracy of diagnosis and treatment options for patients with mttochondrial disease. 3. Advocating for patients and ensuring their voKes shape the research. care and policy that affect their lives. 4. Educating and raising awareness of mitochondrial diseases to the public and the medical community, to increase reco8nition of these rare condition5. 5. Generating voluntary income frorn a diverse portfolio of individuals. t￿sineSses. and charitable trust5 and foundations to fund our work. We are pleased to share our main achievements and progress in these areas throughout 2024125. Research Since 2008 The Lily Foundation has invested heavi￿ rn dtagnostic research, tncluding the Lity Exome Sequencing Proiea. helping to diagnose more patients and identify new disease-cau5ing genes. Our strategy continues io involve close collaboration with NHS diagnostic services. clinicians and research institutes. enabling the sharing of data and resources to streamline dia8nostic pathways. Geneti¢ diagnoses support patieni management. enable famity planning options such as prenatal testing and IVF, and provide the foundation for de¥elopin8 new treatments.

Dowsign Envdtye ID.. 88D8002>802E•B1-82214)30134A11A01 The Lily Foundation Company Limited by Guarantee Trustees. Annual Report {Incorporating the Directorfs Report) (¢ontlnued) Year ended 31 August 2025 Precislon Medi<ine Dia8nostl¢ Project In 2023124 we launched the four-year Lify PrecIs￿n Medicine Diagnostic Project. During 2024125 the project moved inio recrurtment and Èarty delNery, with the first diagnoses now being returned to patients. RecTur(ment sites include UCLH. Oxford, Northern Care Alliance (Manchester), Moorfields, Birmingham. GOSH. Gu￿S and St Thomas,. and Cambridge. with further srtes expected to open. The project is expeaed to increase mitochondrial disease diagnosis rates by around 20%. By August 2025, 112 patients had been recruited. resulting in nine confirmed genetic dtagn05es and two novel genes cuirently under review. To support delNery. The Lily Foundaiion funded a Senior Translational Clinical Screntist and additional project infrastructure. including bioinformatics and project Management support. Trealrnenls Research During 2024125 we paused our annual Treatments Research Call while reviewing our research strategy, but we continued to manage a stron8 Portfolio of funded studies. Three projerts from the 2023124 call are now underway, exploring immune pathways in mitochondrial disease, developing an mRNA-based gene therapy for MNGIE, and testing wearable technology to support balance and exercise at home. A Siudy validating mrtochondrial disease rating scales is also underway. with completion expected in 2026. Acros5 the wider portfolio, around len stvdies remain artive. wtth cornpletion expected by the end of 2026. Progress Includes multiple publications arising from projects investigatlng epilepsy. biomarker5, cardiomyopathy, vestibular dysfuncth)n and rnrtochondrial DNA gene therapy. feArc In January 2025. the LrfeArc Centre for Rare Mitochondrial Oiseases was officialty launched. The Lilv Foundaiion leads Patient and pu￿1{ Involvemeni and Engagemeni IPPIEI act¥vitie5 for the Centre. This includes a programme of community webinars on topics such as emotional wellbein& physiotherapy and living well wilh mitochondrial disease. Lily representatives sit on the Centre Leads Commsttee and several working gTOUPS. Our communication5 work has supported the Centre's launch through accessible research content, including updates shared our Research Zone. Fundin8 has been allocated to recruit a part-time PPIE 5petialist to further develop ihis work International collaboration has abo strengthened. Durin8 the year we pined a joint research call led by the UMDF and the Mito Foundation. contributing in 2025126 to a project at Northumbria Universty. and partnered with GOSH Chanty on their 2025126 research call.

r)oDJsign Erbyelope ID". B8DatsJ2>802E44814221.030134A11AOI The Lily Foundation Company Llmtted by Guarantee Trustees. Annual Report (Incorporating the Directorfs Report) (¢oftWthlU Year ended 31 August 202S Lookln8 Ahead A key priority for 2025126 will be progressing plans for the UK Mitochondrial Disease Research Institute. A roadmap has been developed with stakeholder engagement underway lo agree priorities. governance and funding approaches. Continued investment Trn diagnostic innovation, translational research and collaboratwe partnerships will help accelerate progress towards effective treatments and improved outcomes for patients and families. Patient and Family Support As diagnosis and awareness of mitochondrial disease increases. demand for 5UPPOrt seNices continues to grow. The li￿ Foundation remains the UK'5 leading tharty provKlin8 dedicated support to people affected by mitochondrial disease. Our Patient and Farni￿ Support programme provides a coordinated package of prartical, ernotional and educattonal 5UPPOrt, designed to complement clinical care and address the wider impact of mitochondrial disease on daity life. The programme includes.. Helpline and peer support We are often the first point of contact for families following dia8nos5. Through our telephone helpline, email and social media channels, we offer practical guidance. emotional reassurance and signposting to other specialist services where appropriate. Our closed Facebook peer support groups continue to grow, providing patients and families with a Safe and accessible space to connect with others facing similar challenges. In addrtion. Objr community-based 5UPPOrt activities provide opportunrties for families io find local connection5 in- person with others who understand the realities of INing with mrtochondrial disease. In 2025 we also launched our Zoom Room webinars. a series of online sessions hosted by prtsfessiona15 des￿rted to help farnil*s navigate the day-to-day realriies of INing with mrtochondrial disease. 83 8uests tuned in to the first two 5e55ions. with a fvrther 322 views via YouTube where the recordings are available for those who couldn't join live. P5y¢holo&rical Support We ¢ontTrnue to work with Rareminds to deliver Spec￿1151 counselling for the mitochondrial community. Between January and Detember 202S the service deliVe￿d 230 individual ¢ounselling sessions and 92 couples. sessions, providing vital emotional supFK)rt for patients, parents, partners and bereaved families. The specialist psycholo8i¢al support cln have a significant impart. w¢th BO% of

Dowswjn Envelope ITr. B8DW2&8D2E4481-8221￿3o134A11AD1 The Lily Foundation Company Limited by Guarantee Trustees. Annual Report (Incorporating the Dlrectorfs Report) fLX¥rtI Year ended 31 August 2025 surveyed patients reporting the sessions made them feel more resilient. whibe 70% felt less isolated and 70% feft better equipped to manage their lor their thihl'sl condttion. Consultant Clinical Neuropsychologist Ben Marrarn has Continued to provide 5pecialtst support for complex cases. From 2025126 this se￿iCe will to a consultancy basis to ensure access to expertise when required. Impr￿On8 the Care Pathwav Building on Lily-led researth into the diagnostic journey. we developed a Lity-brandod patient information pack for newty diagnosed families. Created with clinical teams in Newcastle and UCL, the pack provides clear information and signposting at diagnosis. Distribution to metabolic units across the UK and Northern Ireland will begin in 2025126. Resldential Support Weekends Our residential weekends remain a comerstone of community support and continue to grow in popularity. In 2024125 we delivered= Young Adult Weekend: 48 attendees Famiw Weekend-. 295 attendees representing 54 families Adult Weekend.. 102 attendees These events bring together emotional support, edu¢ation. peer connection, expert-led medical sessions and much-needed respite in a safe. inclusive environment. Families often describe these events as a 'lifeline'_ helping to reduce i501at40n, increase resilience and improve emotional wellbeing. Following attendance at our Family Support Weekend in 2025, 92% of respondents felt their famivs wellbeing had been positively impacted. 88% felt more connected to the mito community. and 80% felt more confident in managing the challenges of mbtochondrial disease. Livs Wish Fund Lily's Wish Fund provides practical financ431 support to families facing the often-s￿nIflCant additional pressures that come wrth mitochondrial disease. A drdgnosis can affect every part of life, brin8lng emotional strain. finaneial uncertainty ènd the need for costly adaptatiofts or specialist equipment. Through the Wish Fund, Lity helps families access one-off item5 and support that ¢an make day-to- day life easier. safer and more enjoyable- from specialist equipment and home adaptations to respite breaks.

r)ocu&gn ErNelow ID.. 8BfMw2M02E44814221-030134A11AD1 The Lily Foundation Cornpany Limited by Guarantee Trustees, Annual Report (Incorpornting the Dire¢torf$ Report) (Mtttl Year ended 31 August 2025 Demand exceeded expectations during the year. with seven faMil￿S supported. The programme will continue in 2025126 with a reviewed struciure to ensure sustainabilty. Looking Ahead Overall, our priority for the coming year is to ensure support servi￿5 remain responsive, sustainable and 3ble to meet the evofving needs of the mrt¢xhondri31 community. As demand continues to grow, we will focus on st￿ngthenIng and refining our offer so that patients and families Can continue to access practical. timefy and rneaningful support. Alongside this, we will continue to Strengthen our impact framework so that we can better understand and MO￿ C￿OrlY demonstrate the dtfference our services make to families. Advocacy- Empowering the Patient Ensuring that patient voices shape research. care and policy remains central to our work. Patient and Public In¥ol¥ement IIMPAcn IMPACT, our Mitochondrial paI￿nt Advisory Comrnittee, has grown into a network of around 70 Palients. parents and caregivers. Members contribute to researth desEn. patient resources and policy discussions. During the year IMPACT supported projects including the development of a patient research toolkit and a qualitative study exploring reproduciive decision-making among women with mitochondrial DNA mutations. The group also contributed to a Medical Research Council grant proposal examining menial health and mrtochondrial disease using MRI and wearabk technology. IMPACT played a key role in the LrfeArc Centre's inaugural meetin& delivering a PPI workshop that signrficantly increased professional confidence in working with the mitochondrial community. Fundift8 has ten alk)cated for a part-time PPI coordinator to support the programme's continued growth. Expern¢e ol Diagnosis Study During the year we delivered our h.rst Lity-led ￿Search study exploring experien¢es of receiving a mitochondrial diagr￿S￿ in the UK. The suryey received 176 responses and highlighted signifTrnt variation in diagnostic experiences and limited psychological support at diagnosi5. FindinEs were presented at the UK'S largesi mitochondrial conference and have prompted strong calls for servKe improvefflents. Phase 2 interviews have received ethical approval and will inform advocacy for improved diagnostic pathways and specialist genetic counselling support.

OocusHJn En¥elope ID". 8808002>802É44B1-8221-030134A11A01 The Lily Foundation Company Limited by Guarantee Trustees. Annual Report (Incorporating the Directorfs Report) (c￿￿￿￿•￿) Year ended 31 August 2025 Access to Treatments We continue to advocate for equitable access to emerging treatments. Following the birth of eight healthy bèbies using mitochondrial donation techniques in 2025, The Lily Foundation contritsjted to national and international media discussions supporting wider implementation. We welcomed NICE (National Institute for Health and Care Excellence) approval of Idebenone for LHON ILeber Hereditary Optic Neuropathy) in England and supported patient expert invofvement in the appraisal process. We a￿ a15Q SUPPOrting the anticipaied appraisal of MT1621 for Thymidine Kinase 2 deficiency, potentially the first disease-modifying mitochondrial treatment available on the NHS. Through engagement with regulators. international partner5 and Conferences. we continue to ensure the patient voice inforrn5 emerging therapies. Awarene$5 Raising awarenèss of mitochondri31 disease remains a vital part of The Lily Foundation's work. Through media engagement. conferentes and digttal communications. we aim not ofi￿ to increase visibility of a rare and often misunderstood condition. but also to ensure that patients and farnilies can attess trusted information, feel less isolated. and see iheir eXper￿nceS reflected and understood. During the year, we ¢ontinued to strengthen The Lily Foundation's role as a leading patient or8anisation and a trusted 59urce of Trnformation for the mitochondrial disease community. Our communications f¢XU5ed on quality, relevance and atcessibility. wrth greater emphasis on video. anirnation and story-led content that brought lived experience and expert tnsight to a wider audience. Our social media arnbassadors also helped amplfy authentit voices from acr0$5 the community. OUT digital charbne15 continued to grow, wirh partitularly stron8 progress on InstaEfam1+19%1. Linkedln1+33%1 and TikT0k1+2￿1. while en8aBement remained well above typical nonprofit benchmarks. Our websrte remains an importani source of support and information, with nearty 30.OC(J ¥islt5 to the homepage last year. Despiie fluttuatitins in traffic linked to technical changes in analytics and cookie policies. performance recovered strongly from ear￿ 2025 onwards. Durin8 the year. we continued to strengthen patient information content, intluding the13unth of new syndrome-5pecific pages such as

Docus*an En¥eknte IO". B8D8IY)2>802E44B1-8221-030134A11AOI The Lily Foundation Company Limited by Guarantee Trustees. Annual Report (Incorporating the Directorfs Report) Year ended 31 August 2025 Leigh syndrome and LHON. alongside a new blog 5erie5 and onBoin8 improvements to accessibility and search visibilty. In January 2025, we launched the Research Zone to make complex research developments more accessible to pat￿ntS and families. through interviews. articles and short videos. The content generated over 46.0￿ views across platforms between January and July 2025. wrth particular strong interest in short-form video updates from researchers. This response highlighied the communivs appetite for clear. accessible research communicat¥on and reinforc￿ the importance of helping families Stay infomied about progress in the field. Fundraising Fundraising remains vital to The li￿ Foundaiion's ability to sUp￿rt patients and families. raise awareness of mitochondrial disease and invest in research. We are incredibly grateful to the donors, funders. partners and supporters whose generosity and cornmr¢meni make ths work possible. The chariV5 performance durin8 the year was strong and alEned with it5 0bjertive5. 5LbPPQrted by increased income from sporting events and higher grant funding compared with the prior year. During 2024125, fundrai5in8 activity focused on comrnunity and individual 8Ning. challenge and spec131 events. trusts and foundations. and corporate partnerships. All fundraising was carried out directly by The Lity Foundation team and monitored throu8h project plannin& KPIS and safeguarding procedures. All fundraising staff have regular face to face meeting Wlth senior leadership with KPIS and objectives in place. We monitor all commvnity fvndraising through regular contact and our customer relationship management ICRMI system. No fundraising complaints were received during the year. The charity is not currently registered with the Fundraisin8 Regulator. but has plans to in the future. Community and Individual Giving PublK fundraising continues to be the foundation of Lilvs income. supported by a loyal and hghly en8a8ed communtty of families. friends and supporters with a strong personal cOnneCt￿n to the cause. Supporter-led fundraising and 5POrts challenge events remain particular strength5 durin8 the vear. Improved stewardship. refreshed supporter materials and partnership5 With third-party event providers expanded participation opportunities. New initiative5 such as ihe Lrly Skydive and an online auction also helped divers￿ income. while individuals. schools and local groups continued supportln8 the charity through a wide range of evenis. 10

Oo¢u8pan Envekjpe ID.. 88D6WIM02E4IB1-8221-OJ)134A11A01 The Lily Foundation Company Limited by Guarantee Trustees. Annual Report (Incorporating the Directorfs Report) Year ended 31 August 2025 Special Events Although the Lily Ball was noi held during the year. other evenis performed well. Our Comedy Nights and GolF Days continued to generate income and en8a8ement. while the launch of a Manchester Comedy Night helped broaden our geograph reach and introduce Lity to new audience5. Corporate Partnerships Corporate fvndraising continued to develop during the year, wtih progress in tr)th corporate sponsorship and strengthened relat￿nships. We a150 took a more proactive approach to identifying and enÈaging with potential Charity of the Year and longer-term partners. successfully securing new partnerships wrth Eco Green Group and Infinty Management. Grants, Trusts and Foundatiuns We continued to pursue grant funding to support both research and wrfler charitable activitie5. While this remains a developing area of fundraisin& it ￿ an increasingly important part of LI￿'S lonBer-tem income mix and a key opportunity to diversify funding and build resilience. Looking Ahead In 2025126, we will focu5 on strengthening and diversrfying incorne streams while deepening supporter engagement. Thbs includes refining our events portfolio, developing more strategic corporate partnerships. growing individual and community fundraisin& and taking a more structured approach to trusts and foundations. Alongside this. we will continue to strengthen our fundraising sysiems, supporter journeys and long-tem) plannin& helping to ensure our fundraising model remains sustainable and capable of supporting Li￿S future ambitions in research. support and advocacy. Flnandal positlon The financial statements are set out on pages 25 to 27. The financial statements have been prepared in accordance with the Statement of recommended Practice for Accounting and Reporting by Charities IFRS 1021 issued by the Chafitres CommiSs￿n for England and Wales. The trustees consider the financial perfomiance of the charity during the year to have been satisfactory. Total income for the year ended 31 August 2025 was £1.094.01512024.. £974.3891 and total expenditure was £1.079.84012024= £1.414.0751. The Statement of Financial Activities shows net surplus for the year to be É14,17512024= net deficr( of £439.6861. Unrestricted reserves at the yèar 11

DO￿51￿n ETh%*bpe ID. 6aoaiyJ2>8o2E.84B14221-￿l34AIlA0l The Lily Foundation Company Limited by Guarantee Trustees. Annual Report (Incorporating the Directorfs Report) Year ended 31 August 2025 end. before designation to specific charitable attivities stood at £883.34012024-. £899,401). The financial perfomiance for the year ended August 2025 was strong. driven by increased income from sporting events and htgher grant funding compared with the prKJr year. Expenditure reduced vear-on-year dve to the successfvl implementation of enhanced cost-control measures. The principal sources of funding are through individual donations and Ofganised fundraising events. Alongside donation5 from corporate partners and grant fundin& these income streams ensure we have sufficient resources to fund research, raise awareness. and support Pat￿nts and families affected by mitochondrial dbsease. In the year, in addrtion to recognising £91.921 of expenditure relating to new research initiative5, the charrty also paid £267,616 towards research projects that had been approved and committed to in prior years. As drscussed in the Achievements and Performance seaion above, in 2024125. we paused Ouf annual Treatments Research Call in order to reawss and refine our overall research 5trate8y. The charity h3s been focusing on devebping a refreshed strategy for future research investment, ensuring that re50ur¢es are allocated effert4¥ety to maximFse impact. Policle5 on ReseThes The Lily Foundation's reseryes policy remains unchanged from the prev￿US year. following the Comprehensive review carried out and approved by the Board during the financial year en(led 31 August 2024. The policy continues io ensure a balan￿ between financial stability and maximising resources in support of the charl￿5 mission. Reserves Pollcy Overview The charrtrfs policy is to maintain a minimum level of free reserves equi¥alent to six month5 of operating costs. covering: Fixed charity running costs Salary and frpelance costs Essential variable costs required to support ongoing operations This approach ensures the Foundation retatns a prudent financial buffer against unexpe¢ted changes in income or expenditure, while enabling fvnd5 to be deployed effectively and w((hout unnecessary accumulation. The six-month reserve requirement for the year ended 31 August 2025 is £449,565 12024.. £394,527). 12

Oocusign Envelope ID. B8D80023-802E4461-8221-0>)134A11A01 The Lily Foundation Company Limited by Guarantee Trustees, Annual Report (Incorporating the Dlrectorfs Roport) (c￿liau8￿) Year ended 31 August 2025 Appllcatlr)n of the Pollcv Where free reserve5 exceed the minimum level required under the policy. the trustees review the position annually in light of the charl￿S financial 0￿100k. strategic priorities and planned charitable activity. At 31 August 2025. free reserves remained above the minimum level Set by the policy. The tiustees have therefore designated a proportion of unrestricted fisnds for specifit future charitable activities and strategic priorities. These deswdnarions reflert planned use of funds. Whi￿ retaining an appropriate level of financial resilien￿. The trustees tontinue to take the ¥￿W that a separate reseThe to cover the cost of organising fundraising events is unnecessary. as h￿lOrical￿ such events have either covered their direct costs or generated a surplus. Events would not proceed if J loss were anticipated. Reser¥es Posilion at 31 August 2025 At the financial year end, the charity held free reserves of £449,56512024..£394,5271. Free reserves represent total reseNes excluding desgnations, fixed assets and restricted funds. Of these free reserves: An amount of £449.565 has been set aside in line with the ¢haritl5 six-rnonth reserves policy. A further £432,452 has been designated to specrfic charitable activities12024.. £504￿74}. This leaves £0 In unrestrirted Unde$￿nated reserves. Restricted ￿ServeS at 31 August 2025 totalled £71.34612024.' £41,110). all of which have been allocated for use in accordance with the relevant donoT-imposed COndn￿nS. Ongoing Review In keeping with Charity Commission guidance, the trustees regularly monitor the appropriateness of the rese￿e$ level. Should the charitls financial tircumstances or strategic priorrties change. the trustees will revi51t and, rf ne¢e55ary, revise the policy to ensure it femain5 aligned with the chaTiW5 operational needs and long-term sustainability. Grant Maklng Policy Once a year at the AGM. tnjstees decide the main focus of the charitys grant making activities for the coming year, in line wrth the main charlty aim5 and objectives. The CEO and relevant staff then engage directly with orgènisations that rnay be able to fulfil those objectrves and onte satisfied. contracts are drawn up and award5 are rnade. 13

DoGustgn EnweS)pe ID." B8D8fy)2M02E-8481-8221-030134A11AOI The Lily Foundation Company Limlted by Guarantee Trustees, Annual Report (Incorporating the Directorfs Report) (¢ortlft Year ended 31 August 2025 The charity has established it5 8r¥nt making poliry to a¢hie¥e its objerts for the pvblic benefit. The charity's aim is io improve the INes of patients with mitochondrial disease and their families. to raise awarenes5 of the condition and to seek effertNe treatrnents and a permanent cure in the future. We review our grant rnaking policy annually to ensure that it reflects the charity's objects and therebv advances public benefit_ Our research and educational programmes fund students. researchefs. ￿Search institution$ and healthcare bodies who use these funds in their work to impr¢)ve the lives of pat*nts with mitothondrial disease and their carers, by d￿elopIng ther3pies. w)tential medicatrons, managing symptoms and impfoving ihe personal care of sufferers. The charrty invites applical￿nS for research grants from institulions by advertising on our website and social media. at specialist conference5, ond via dirert ernail. Eligibility is restrirted to applicants having an expertise in the field. in order to ensure high qualrty ￿SUItS for mrtochondrral disease sufferers. Institutional applicants submr¢ a sumrnary of their proposals to the trustees in a specific format, together with outline ethics approval. The charity follows best prartice in maintaining the independence of research funding and ensuring that sponsored researchers and research institutions abide by best practice in research ethics and anirnal testing,. our aim i5 to maximise the efficary of Ihe research programme whilst minimising the likelihood of harm to research volunteers and animals. Applications made in the correct format are peer reviewed by our international expert scientific review board a8ainst the scientifK research criteria established by our Research Sub Committee and OLbr research objertives. Continuation of the grants is subject to a six-monthjy assessment by the Research Sub Committee. In all cases. continuation of funding is subjett to the research undertaken being in the interests of the charity and a satisfactory pro8ress a55essment. Our patient support programmes provide short b￿ak5. specialtst equipment and hospita accommodation for patients with mitochondrial disease. through direct contart wilh the service provider. Support is offered on a first-come. first-served basis and patients are not means tested. Plature of the Governin8 Do¢ument c¢nstilulion of the tharity Constituted a5 a Private Lirnrted Company operated by a Board of Trustee5. Governed by a Memorandum and Articles of Association and a Governing Document folk)wing the Charrty Commissioners template. The meth<Kls adopted lor the reuuilment, appoiThtmenL induc16on and training of new trustee$ We have a recruitment process 14

DovJ5#JD K). 880aQD2>a02E44B1-8221.030134A11A01 The Lily Foundation Company Lirnited by Guarantee Trustees. Annual Report (Incorporating the Directorfs Report) (Gon&nuedJ Year ended 31 August 2025 Advertising of the position via website, social media platforms, word of mouth • Inteiview process with board members, members of the SLT and patient representatives • Board approval 15 given for the success￿1 candidate The candidate then decides whether they will accept the position. Once accepted, the trustee has a period of onboarding which include5 being given promotional literature about the charr(y and directed io the charrty website for further background information. introdurtory meeting with the CEO and other staff to meet the team and urbderstand the charitv structure. They are encouraged to ask questions and are gNen infomiation about their obligations as a trustee of the charity. Any required training is provided. - Throughout their term. trustees are encouraged to attend appropriate external training events and reading where this will facilitate the undertaking of their fole. The tyganisational strutture of the Charity and how dÈtlsiMs are made The board of tTUStees consisted of 9 individuafs ai 31st August 2025. All policy decisions are made by the Board with any final decision in the event of a tied vote being made by the Chairperson. Elizabeth Curtis, as CEO. Ts responsible for the day.to-day organisation of the Charity. working closely with the chairperson and senior management team on decision making matters. In addition. there are several sub-cornmittees to organise different aspects of the charrtrfs work. There are regular board meetings throughout the year to disCU55 charity matters. culminating in an AGM. Sub-commtitees covering evenis. fundraisiw patient support and awareness normalty meet quarterty- Sub-committees for finance meet every two months. Key Management and PefSonnel ReM¢￿erati￿1 The Board of Di￿(tOrS and the Senior Leadership Team ISLTI make up the key management of the charity and are in charge of directing and controlling the strategic leadership. The SLT manage the day-to-day management of the charity- All dirertors give their time freely and no director recewed remuneration in the year. The pay of the senior staff is reviewed annualty and normally increased in accordance with the rate of inflaiion. In view of the nature of the charity. the directors benchmark against mid-point pay levels in other charitable organisaiions of a simiLir size. with flexibility to adjust upwards for additional responsibilr(res.

or￿u5￿Jn En4*lope ID.. B8D8O02>802E4481-8221￿30134A11A01 The Lily Foundation Company Limited by Guarantee Trustees. Annual Report {Incorpwating the Direclorfs Report) Year ended 31 August 2025 Rlsk Management The trustees Conduct annual reviews of the mapr risks to which the charty is exposed. and ihese are recorded in a risk register. Where appropriate. systems or procedures have been established to mitigate the risks the charity face5. The charity has identified that financial sustainability is the major financial risk for the charity. A kev element In the management of firbancial risk involves produrtion of quarter￿ management accounts with ana￿tiCal review of income and expenditure. as well as actNfe management of available liquid funds to settle debts as they fall due. and of trade debtors and credNtor5 balance5 to ensure sufficient working capital. E￿ernal risks to funding are regularly reviewed and the charity's strategic plan addresses these rb5ks and allow5 for the dNersification of fundin8 and a¢tivities. Internal control risks are rninirnised by the ¢learfy defined proCedu￿S for authorisation of all transactions and projects. Non-financial risks arising from operational artNrties. compliance. and environmental fadors have also been identified and these risks are managed by having robust policies and procedures in place. and regular awareness training for staff working in these operational areas. All procedure5 are periodKalty reviewed to ensure that they continue to meei the needs of the charity. Share Capital The company 15 limited by guarantee and therefore has no share caprtal. The members of the Board of Trustees of the Charity durin8 the year ended 31st August 2025 and at the date the report and accounts were approved were.. Mrs Helen Rider Mr john Symons Mr Benframin Carter Mrs Rupinder Bain5 Mr john Spyrou Mr Dean Curtis Mrs Claife Gore Mr Ri¢hard Kirk Mr Oean Booth All the direclor5 of the company are abo trustees and Tnembers of the charity. and their responsibilities include all the responsibilities of directors under ihe Companies Acts and of trustees under the Charitte5 Acts. 16

Doujsiw Envdcpe ID. B8Da002>802E44b1-8221-0301W411A01 The Lily Foundation Company Limited by Guarantee Trustees, Annual Report (Incorporating the Directorfs Report) Year ended 31 August 2025 Reglstered tharlty name The Lily Foundation Charity registration number 1122071 Company registration number 064(M)879 Principal office and registered 31 Warren Pa office Warlingham Surrey CR6 9LD The trustees Mr5 H Rider Mrj Symon5 Mr B Carter Mrs R Bains Mr J Spyrou Mr D Curtis Mrs C Gore MrR Kirk Mr D Booth Company s￿retary Mrss Hanks Auditor Moore Kingston Smith LLP Chartered Accountants & statutory auditor 6th Floor. 9 Appold Street London Unrted Kingdom EC2A 2AP Bankers 8artlays Bank Pl¢ One Lhurchill Place London E14 5HP 17

Dooj￿gn Envekpe ID." 88D8fK12>802E-84B1-8221-ts30134A11AOI The Lily Foundation Company Limited by Guarantee Trustees. Annual Report (Incorporating the Directorfs Report) Year ended 31 August 2025 The trustees. who are also directors for the purposes of company law, are responsible for preparinB the tru5tees' report and the financial statements in at¢ordance wfth applicable law and United Kingdom Accounting Standards Iunited Kingdom Generally Accepted Accouniing Practice). Company law requires the company trustees to p￿pare financial statements for each year which give a true and fair view of the slate of affairs of the charitable company and the incoming resources and application of'resources. including the income and expenditure, for that period. In preparing these financial statements. the trustees are fequired to= select suitable accountin8 policies and then apply them consistentty- observe the methods and winciples in the applicable Charities SORP- make iud8ments and a¢countin8 estimates that are reasonable and prudent,. prepare the financial staiements on the going concern basi5 unle55 It is inappropriate to presume that the company will continue in business. The trustees are ￿SponSible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable thern to ensure that the financial Siatements comply with the Companies Art 2006. They are a150 responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. Auditor Each of the persons who is a trustee at the date of approval of this report confirms that.. so far as they a￿ aware. there ￿ no relevant audrt infommtion of whrch the company's auditor is unaware.. and they have taken all steps that they ought io have taken as a trustee to make themselves aware of any rplevant aud¢t inf0m￿tIOn and to establish that ilie company'5 auditor is aware of that information. Small tompany pto¥islons This report has been prepared in accordance with the provisions appli¢able to companies entitled to" the small companies exemption. 18

thcusigTr En￿lOpe ID." B9080023-802E-84614221-030134A11AOI The Lily Foundation Company Limited by Guarantee Trustees. Annual Report (Incorporating the Directorfs Report) (c Year ended 31 August 2025 The trustees, annu31 report was approved on of trustees by-. 211512026 and sgned on behaw of the board 49SfjPID*321B4ei_ Mr Dean Booth Trustee 19

Do￿Sign EnvÈh)p8 ID". B808002MOZE•81.8221-030134A11A01 The Lily Foundation Company Limited by Guarantee Independent Auditor's Report to the Members of The Lily Foundation Year ended 31 August 2025 Opinlon We have audited the financial ststem$nts of Tho Lity FOur￿a￿.￿ Ithè'company'l for the year ended 31 August 2025 which cornprise the Statement of financtal activitie5 (including income and expenditure account). ststement of financial po51tion. statement ol Gash tlows and the rdated notes, in¢luding significant accouniing polTrcies. The financial reporting framework thal has been applied in their preparatit>n is appI￿able law and United Kingdom Accounb"ng Standards. including FRS 102 Thè Financial Reporting Standard applicable in the UK and Republic ol Ireland (Uniled Kingdom Generally Accepted Accounting Practice). In our opinion Ihe f￿anCIal 5talements= give a true and lair ol Ihe state of Ihe company's affairs as at 31 August 2025 and of its incoming resijurces and apph"catron of resour¢es. rncluding its in¢ome and expenditu￿, for Ihe year then ended.. have been property prepared in aCCC&dan￿ Tmth United Kiwm Generally Accepted A¢counlin9 Pra¢tice-. have been prepared in accordance with the requirernents of the Companie5 Act 2006. 8asis for opinion We condu¢ted our authi in 8¢cordance ￿ Iniemath)nal s￿r￿ards on Audib'ng IUKI IISAS IUK}l and applicable law. Our responsibilities those standafds a￿ further described in thè auditorfs responsibilities for the audit of the financial statements section of our reporl. We are independent ot the company in accordance wth the ethical requirèments that are relevant to tyjr audit of th8 financial statement$ in the UK, including the FRC'S Ethi¢al Standard, and we have futfilled our other ethical responsibilities in acceidance ￿ thèse requirements. We believe that the audit eviden¢e we havè ctllained is sufficient and appr¢)priale to provide a basis ￿ our opinion. Conclusions r•lating to going concern In auditing the financial statements. we have conduded that the trustees. use of the g)ing concern ba￿S ol accoLtnling Ifb the preparation of Ihe financial sfatements is appropriate. Base¢J on the work we hav8 performed. we have not identifiéd any material uncertainties relating to events or conditions that. indNidualty or colleckn"¥ely. may cast significant doubt on the company's ability to continue as a going concem for a per￿ of at ￿ast twelve months from when the financial ststemenls are authorised for issue. Our responsibilitie5 and the fespon5ibilities of Ihe trustees wth reskwt io going concwn are described in the relevant sections ol this rwrt. 20

Docysign ID.. 88D8002>802E-8181-82214130134A11AOI The Lily Foundation Company Limited by Guarantee Independent Auditor's Report to the Members of The Lily Foundation (continuedl Year èndod 31 August 2025 Oth•r inft>rm¥tion The other infc*rnation comprises the lnfcma1i￿ included in the annual report. other than the financial statemènts and our audrtor's report thereon. The trustees are reSponsi￿e for the other Information contained wrthin the annual report. Our Opini￿ on the financ￿1 stalements does cover the other information and, except to the extent othemse eXplic￿Y stated ￿ our report, we do not èxpress any l¢ym of assurance cOnclu￿on there￿. Our rèsponsibility is to read the other inf0m1at￿n and. in doing so, consider whether the other information is materially inc￿$1$1Ènt the fin¥n¢BI siatèments or our kftrNAedge obtsined in the ourse of the audit or othèrwse appears to ￿ materially misstalèd. If we identify such matèrial in¢￿SIsten¢1es or apparent material misstatements, we arè required to detèm)inè whether there is material misstatement in the financial statement5 Ihemselves. If. based on the work we have performed, we ¢onckxle that there ts a matefial rnisststwnent of Ihis olher inf¢ymabon. we are requir lo r8POrt that fact. We have nothing to report in this regard. Opinlons on oth•r matt•rs prescribed by the Companles Aet 2006 In our opinion. based on the work undertaken in the C￿rse of tha a￿11. the inf0M￿tion given in Ihe trustees. report for the financtal year for which Ihe fina￿la1 statements are Pfepared is consisient wth the financial slatemenls: and th8 trustees. ￿pOrt has been prepared in accordance With appluble legal requirements. Matters on which we are required to rewl by oxception In the light of Ihe knowledge and undèrstanding of thè company and its environmènt obtsined IA the course of the au¢Jit. wa have not identified material misstatements in the trustees, reFort. We have Tr)thing lo report in respect of the follcwn9 matters ￿￿tion to which th$ Companies Act 2006 ￿qUireS us to report to yw rf, in our opinim". adequate aeeounting records havè not been kept, or rètums adequate lor our audK have not been recEived frc¥n branche5 not visited by us: or th8 financkal statements are not in agreement wAth the aCc￿n￿"n9 records and rètums,. or certain disdosures of truste8s' remunerats.on spteffj￿￿ by law are n¢X made." or we have not r8ceived all the information and explanations we require for our audrt," or the trust8es were nol entitled to take a¢Jvantage of the small ¢OmPan￿$. exemptions in preparing th• directors. report and frcrfn the requirement to prepare a Strateg￿ rep￿t. 21

DotsJswJn En¥dop210". 88080D2>8o2E-84814221-￿134A11AO7 The Lily Foundation Company Limited by Guarantee Independent Auditorfs Report to the Members of The Lily Foundation (wiii Year ended 31 August 2025 Responsibilities of tru$t¢•s As explained more fully in the trustees. resFonsibilrties statement, the trustees (who a￿ also the directors Ic¥ the purposes of company lawl are ￿ SP￿Sib￿ for the preparation of the financial statements and for being Satisfied that they give a true and fair view, and lor such intemal conirol as the trusteès d8t8rmine is necessary to enable the preparatft)n of financial statements that are free from material misstatemenl. due to fraud or errcy. In prèparing the financial statements, the trustees are resPOn&b￿ for assessin9 the company's ability to continue as a going concÈm. disclosing. as applicable. mattèrs related to g¢ing ¢on¢èm and using the goin9 eoncèm basis of accounting unless Ihè Irustees either int￿d to liquidate the c¢Jnpany or lo cease operations. or have no tsalISt￿ altemative but to do sts. Auditorfs responsibilities for the audit of the fin¥nci¥l $t•tèmÈnts Our objectives are to obtain reasonable assurance abo(rt whether the financial statements as a whole are free from material misstatement. whether ijue to fraud or error. and io issue an auditorfs report that includes our O￿niOn. Reasonable assurance is a high levd of aSSUfance. but is not a guarantee that on audit conflucted in accor¢Yance with ISAS IUK) wll ahvays detect a material misstatement when it exists. Misstatements can arise from fraud ￿ error and are considered malerial rf. individually or in a9grègate, they coukl reasonably expected to influer￿e the ecorK)m￿ deC[s￿nS of users taken on the basis of these financial statements. As part of an audit in accordance with ISAS (UKI. we exercise professiC￿al judgment and maintain prOfeS￿onal sceptscism through￿1 the We also: Identify and assess the risks of material misstatemenl of the financial statements. whelher due to fraud or effor, design aftd perfom) audrt prctedures responsive lo those risks, and obtain audit evidence that is suffKient and appropriale io wovidè a bass for our opinion. The risk of not deiecting a material misstatement resulting from fraud is higher than for one resulting from error. as fraud may invO￿e collusion. forgery. intenlK)nal omissM)ns. misrepresentations. or the overnde of intemal control. Obtain ￿ understsnding of intwnal ojnlrol relevant to Ihe audit in lyder to deS￿n audit proc8dures that are appropriate in the circumstances, t)ut not for the PL¢rposes of expressing an opx'nion on Ihe effe¢ts"veness of the thariiable Company's internal control. Evaluate the appropriateness of accounting policies used and the reasonableness of ac¢ounting ests"mates and relaled disclosures made by the trust89s. Conclude on the appropriateness of the trustees. Use of the ￿Ing concem basis of accounting and, based on the audit evKleneÈ obtained. whether a matèrial uncertainty exists related to events or cC￿dItIOnS that may cast sMJnificanl doubt on the charitable cornpany's ability to continue as a going concem. If we conclude that a mat8rial Vr￿ertaInty exists. we a￿ required to draw attentK)n tn our audiiorfs report to the relaled disclosures in the financial statements or. rf sijch disclosures aTe inadequate. to modify ouf oty"nion. (Xjr conclusions are based on thè audit evidence obtained up to the date of our auditorfs ￿￿￿(. Hthvever, future èvents or. conditions may cause the charitable company to cease to c¢￿tinue as a going concern. Evaluate the overall presentsiion. struciufe and content of the finanoal statements, including the disclosures. and whether Ihe finarrial stalemenls represenl the undersying lransacts.ons and evenls in a manner Ihal achieves fair presenlab"on. 22

OLusHJn Enlop¢10." 88D8Ci12>802E44814221-O>J1W411A01 The Lily Foundation Company Limited by Guarantee Independent Auditorfs Report to the Members of The Lily Foundation (¢LMWnu•d) Year ended 31 August 2025 We communicate with tIK>se charged with wvemance regarding. among other matters, the planned scope and timiThJ of the audit and significant audit findings. including any sonificant deficiencies in internal control that wè ldènkn.fy during our audrt. Explanation as to what ext¢nt the audit was considernd ¢apable of delectirtg wrngul•rities, including fraud I￿e￿laritieS. including fraud, are inslances of nrffl-compJian¢e wilh laws and regulati¢￿$. We design pr(xedures in lina ￿th our responsibilib"&s, outlined above, lo detect material misstatements in respect of irregularities. including fravtl. The exient to which our piocedures are capable of delecting irregularities. indudin9 fraud is detailet1 below. The objecb've5 of rjur audrt in resFeCt of fraud. are.. to identfy and assess th• risks of material misstatement of the financial stalemenis due to fraud.. to rtjlain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, Ihr¢)Jgh designing and implementing appropriate responses to Ihose assessed risks". and lo respond appropriately to instances of fraud ¢y SLtspected fraud identified during Ihe audil. However. the primary responsibility for the prevention and detection of fraud rests with bJth management and those charged with 90vernan¢e of the ¢haritable cc¥mp￿y. Our approach was as follows: We obtained an understanding of the legal and regulatory requirernents appluble to the charity and considered that the most significant are the Financial Reporting Standard applicable in Ihe UK an¢J Repuwic ol Ireland {FRS 1021, the Accounting and Reportiny by Charitiès.. Statement of Recommended Practice appluble to charities preparing their accounts in accordance wth the Financial Rep￿ting Standard appI￿able in ihe UK and Republic of Ir•lanO IFRS 1021 (Charities SORP FRS 102). the Companies Act 2006, the Charities Act 2011 and the crynpany's Arti¢les of Association. We Obtain￿ an undw5tanding of ITh¥ the charity compl￿S with these Tequirements by Lliscu￿r0nS with managerneni ant1 those charged with govemance. We assessed the risk of material missiatemÈnt of the ffinancial siatemenls. including thè risk of material misstatement due to fraud and h¢M it rnit rtr#Jr. by holding discussions with management and those charged wth govemancè. We inquired of management and those charged wth 9)VeMan￿ as lo any known instances of non-compliance c¥ suspectèd non-complian￿ with laws and regulations. Based on this Understar￿lng. we deygrwd spe¢ifi¢ apkvopriate audrt W￿dur&S lo it1entify instances of non-cOM￿lance wth laws and regulatIc￿5. This included making enquiries of management and those charged with 9oveman¢e and obtaining additional ctrroborative evKl&ncè as required. There are inherent limitations in the aud￿¢ procedures described at￿e. Vle are less likely lo become aware of instances of n1￿£0M￿lance wrth laws and regulations that are not closely related to events and transactions reflecled in Ihe finanual statemenls. Also. the risk of not detecting a material misstatement due to fraud is higher than the risk of not detectiro resutb.ng from èrnor. as fraud may invofve deliberate concealment by. for example. for￿ ￿ intentbonal miyepresentats"ons. or through colluson. 23

Do￿J$ign envew ID. B8D8C¥)2&￿E￿4Bl￿22l￿)l3lAIjAOI The Lily Foundation Company Limited by Guarantee Independent Auditorfs Report to the Members of The Lily Foundation (conllmied) Year ended 31 August 2025 Use of our report This rèport is made solely to thè companrfs members. as a bc#Jy. in accordance wilh Chapter 3 of Part 16 of Ihe Companies Act 200fj_ Our audit work has been undertakan so that we might state to tha company's members those matters we afe required to state lo Ihem in an auditorfs report and for no other purpose. To ihe fullest extent permitte(I by law. we do nim 8¢¢epi or assume responsibility lo anyone other than the company and the companws membèrs as a bojy, for our audit work, for this report. or for the opinK)ns we have formed. 9ED5DPCCJ35F445_. Adam Fullerton (Senw Statutory Audikyl For and on behaff of ry)re Kingston Smith LLP Chartered Accounlants & stalulcry audil 6th Floor 9 Appold Street London UK EC2A 2AP 221512026 24

DotrA9n EnvdLye ID.. B8D8fy12>802E4481-8221-W134A11A01 The Lily Foundation Company Limited by Guarantee Statement of Financial Activitles (Including income and expenditure account) Year ended 31 August 2025 2025 Re5tn'cted fvnds Totsl funds Total f￿d5 2024 Unrestricted funds ote Income #nd endowmwts t)onations and legacies Other trading activities Investment income 717.877 99.881 40.088 236.169 954.046 99.881 40.088 769,948 176.394 28,047 Total incom• 857.846 236,169 1.094.015 974,389 Exp¢nditure Expenditure on faisw funds= Costs of raising donations legacies Costs of othèr tradw)g actwiti.es Expenditure on charitable a¢tNrtie5 Total expendlture 1216.5631 {216.563) {162.0471 189,993) {89,991 {218,8871 (567.353} {205.933) 1773.286} 11.033.141) {873.907} 1205.933) 11,079.8401 11,414.0751 10.11 Net iftcomèl{expendilur•l and net movement in funds 116.0611 30.236 14.175 {439,6861 Reconclllation of funds Tolal funds brought forward Total ￿ndS earTi•d fornard 899.401 41.110 940.511 1.380.197 940,511 883.340 71,346 954.686 The statement of financial acb"vffES includès all gains and k)ss8s fecognised in the yaar. All income and expendiiure derive from continuing activib'es. Th¢ notes on pages 28 to 42 fonn part of the8e finawKlal $la¢emenl& 25

DoDj￿9￿ EnvelDpe ID". 88D8[￿&802E￿4@I-8221-11301w1lAOl The Lily Foundation Company Llmited by Guarantee Statement of Financial Position 31 August 2025 202$ 2024 Fixed assets Tangible fixed assets 17 1.422 2,756 Current assets Debtors Investments Cash at bank and in hand 18 19 131,364 155.OLX) 1.083,496 67,886 1,490,430 1.369.860 1.558.316 Creditors: amounts falling du• within on• year Net curr•nt ass•ts (412,542) 1444,7691 957.318 1.113.547 Total assets less cunent liabilities 958,740 1.116.303 Cr•ditors: amounls falling due after more ¢h•n one year Not assels 21 14.0541 (175,7921 954,686 940,571 Funds of the charity Restricted funds Unrestricted funds 71.346 883,340 41.110 899,401 Total chariiy funds 23 954.686 940.511 These financial stalements have been prepared in ar￿0￿¢ with the provisi￿S applicable to companies subject to the small compantes. regime. These financial emènts were approved by the board of Irustees and authorised for tssue on 2115r2026 , and are 51gned on ￿ha￿ of the board by.. Trustee L)irector Th• rtot•s on pages 28to 42 forni part of ih•s firwn¢ial stat•m•nts. 26

Oocu5ign Enveljpe ID. BBD80Wd>802É-84814221.OX1134A11A01 The Lily Foundation Cornpany Limited by Guarantee Statement of Cash Fl¢)ws Year ended 31 August 2025 2025 2024 Cash flows from opwatlng activ•ties Net incomellexpenditure) 14,175 {439,6861 Adjustments ts.. Depreciation ol tangible fixed assets Other inlerest receivabKe and similar inc(¥r Accrued lincomeyexpenses 2,087 140.0881 {5911 1,935 {28,0471 18,537 Changes in.. Tfadè and other debtors Trade and other ¢redrtors 161,494) {203.3741 (289,285) 1324,8341 {2,606) 125.033 Cash used in operations Net cash used in ¢)perating activities 1289,285} {324.8341 Cash flo¥rt from inv•st*w activities Purchase of tangible assets Purchases of current asset ￿Vestments Interest received 1753) I155,0￿) 36.104 {5731 28,047 Net C8sh (used inyfrom inveslw)g activities 1117.6491 27,474 Met decrease in ¢ash and cash ¢(wival•nts Ca$h and cash equivaltnts at beginning of year Cash and cash equivalents at end of ￿ar 1406.9341 1.490,430 1297,360) 1,787.790 1.083.496 1.490,430 The note$ on pages 28 to 42 form part of Ihese finan¢ial s¢•lem•nts. 27

DouJ5i9n en￿oF4 ￿)". 8808002>802E44BI-8221-030134A11AOI The Lily Foundation Company Limited by Guarantee Notes to the Financial Statements Year ended 31 August 2025 General information The company is a public benefft entity and a FWNate company limited by guarantee, registered in Engbnd and Wales and a registered charity in England and Wales. Tho address of the re9iSt8red office is 31 Warren Pafk. Warlingham. Surrey. CR6 9LD. ststem¢nt of compliane• These financial statements havè been prepared in compliance ￿th FRS 102, The Financial ReF)Orting Standard appliCa￿e in the UK and the RepU￿1C of Ireland.. the Statement of Recommended Practice applIca￿e to eharities preparing thwr at￿nts in accordan¢e with thè Financial Reporting Standard applicable in the UK and Republic of I￿laftd IFRS 1021 (Charities SORP IFRS 10211. the CharLties Act 2011 aThJ the Companies Acl 2006. AecountSng polieles Basss of preparatlon The finartial statennts have been prepared on the historical cost basis, as modified by the revalualion of certain financial assets and liabilitbes and investment prc)erties measured at fair value through income cy exp*￿iLure. Thè financial statements a￿ prepared in sterfing, which is the functional cur￿ncY of the entty. The amounts have been presented to the nearest £ Un￿$$ tsthemse stated. The accountyry pdicies have been applied ¢Msislenlly in the Current and preceding year. Going eOnC•rn The trtjstees and finan¢e committee have reviewed the budget for 2026r27 and f0￿CaSt for the remaindef of the current financial year. The forecast and budgèt show that the ¢harity is a going ¢em to the end of the ftAlowing finanoal y￿r (August 20271 wrth suffi¢i¢nt eash and reseryes to meet liabilities as they fall due_ There are material uncertaintse5 about the chwty's abilty to conts"nue. Judgemènts and key SI￿rets of estimation unc•rtalnty The preparation of the finanrAal slatements requires management to mak8 judgements. estimates and asstjmptions that aff￿t the amounls reported. These estimates and judgemenls are continualty reviewed and are based on axperience and Ot1￿ fauors, induding expectatifMS of future events that are believed (o be reasonable under the circufflstances. Thefe ar& no sNJnifi¢anl areas rewKing material judgements. estimates or assumptions. Taxation The charity is exempt from tsx on income and ga￿S to the exlenl that these afe aFflied to its charitable objèctives. Fund accounting Unrestsicled funds are avadable f(x at the discretion of the Iruslees to lurther any of the ¢haiity's purposes.

DowTr Env2W10. BOD8r•)2M02E44B1.￿2l-93Ol34Al JA01 The Llly Foundation Company Limited by Guarantee Notes to the Financial Statements (e Year ended 31 August 2025 Accountlng policiès {e¢7nUnuedJ Fund accounting (¢thWnu•d) DeS￿nated funds are uniestricted hjnds earmark•J by the trustees for pafticular future project or commitment. Restricled furKls are subjecled lo reslrKtKM5 on thwr exper￿lI￿re dgdared by the dorb)r or ough the tern)s of an appeal. In¢om• Inc(￿ne is a¢¢ounted for when the ¢harrty has entiuement to the frjnds. re￿Ipt 15 probable. and the amount is measurable. I￿ere income Trs received ￿ advan￿ of an event it is defer￿ until the charity is èntitled to the income_ Income frtyn donations and grants is w)cluded in income when Ihese are receivable. Wh donors impose condrtions. which have to be fulfilkd before the charity becomes ents.tled to use such incomé. the incorne is deferred and not include(l in income until the pre-condibon5 for use have been met. Inte￿st is included when receNabk by the charity. Interest on funds held on deposit is included when rec&vabkn and the amount can be measured reliably by the charity.. this is ￿rmalty uw)n of the inlere51 or payable by the bank. Expeftditur• Expenditure is ￿l￿3n1$ed on an accruals basis as a IK4bilrty is inCu￿d. Expondilure includes any VAT which cannot be fully recovered, and is classif*d under headings of the statemenl of financial a¢tivths to whKh rt relates". expenditure on raistrng funds tncludes the costs of all funthaising acti¥iti"es. events. non- charitable trading activities, and the sale of d(x)ated goods. expenditure on charitable activitie5 includes all costs incurred by a charty in undertaking activities that further its charrtable aims for the benefit of rts benefick4riès, including those supprxt costs and costs relalry to the g)vernance of the chanty apports"oTred to charitable acb"vrtiès. other expenditure includes ￿1 eXp￿ditUre Ihat is neither related to raisirvJ fvnds for the eharity nor part of its expendrture on chavital￿e activrtiès. All costs are allc¢8ted lo expendilure ¢ategorie5 reflecling the use of the resource. Direcl o)sts attributable lo a single activrty are allocaled directly to that activity. Shared costs are apporti¢y)e(I be￿een the activities Ihey contribute to on a reasonable. justifiable and conslstent basis. Grants payable are payments made to third parties in the furtherance of the charitable objects of the charity. In the case of an unconditional 9rant offer this is accrued once the recipienl has been nobfied of the grant award. The nob"f￿tIOn gives the ￿l￿"ent a rèasonable expectabon that they will receive the grant. Granl awards that a￿ subject to the recipient fulfilling perfomance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condiliffi attaching to that granl is outsidè of thè eontrol of the charity Provisions for grants are made when the intention to make a grant has been communicated to tha récipiènt but there is uncertainty as to the timing of the grant or the amount of grant payable. 29

Oocusign En%%lope ID". 88D81Y)23-802E-64e1-82214)30134A11A01 The Lily Foundation Company Limited by Guarantee Notes to the Financial Statements {C￿￿m Year ended 31 August 2025 Accounting poI•cigs Operating l•ases Lease payments are recognised as an expense over the lease terni on a straighl-line basis. The aggregate benefit of leas8 incentNes is recognised as a reduction to expense over the lease twm. on a straihl-line bass. Tangibl¢ assets Tangible assets are initialty recorded at cost. and subsequenuy $tated at cost less any accumulated depreciation and impatrmeni thse5. Oepr¢ciation Depreciation is calculated so as to Wr￿le off the cost or valuation of an assei. less its residual valuè. over the useful economi¢ lrfe of that asset as foll(yws-. Fixiures & Fittings Equipment 2S% straight ￿'ne 25% Stra￿h1 lir Impairmont of fixed ass8ts A review for indicators of impawment is carried out at each reporting date, wilh the recoverabl• arnount being estirnated where such indicatrrfs exist. Whwe the carrying valu• exceeds the recovèrable amount, the asset is impaired aCccWding￿. Pmr impaiments are also ￿viewed for rK)ssible reversal at each rewrtin9 de. Ihe purposes of impairment testin9, when it is n(A posyble to eslimale U)e recoverable amount of an individual asset. an estimate is made of the rewverable amounl of th¢ ¢ash- generating unit to which the asset bdwgs. The cash-generating unit is the 5rnal￿t identifiable group of assets Ihat indudès the asset and generales cash inflw$ that largety independent of the cash inflow5 from other assels or groups of a5sel5. Financial instruments A financial asset or a financial liability is recthjnised onty when the entity beccnes a party to the ontractual provi5iMs of ihe instrument. Basic financral ￿strUmentS are inilially recognised al Ihe amount receivable or payable induding any related transacb.on costs, unless the arrang&ynent consttiutes a financing transaction, wharè it is re￿nised al the present value of the fijture payThents discounted al a market rate of inte￿t for a similar debt instrument. Current assets and currenl liabilities are subsequently measured at the cash or other consideration expected to be paid or receNe(l and not discounted. Debt instruments ¥e sub5equentty meastlred at amc1ise¢J cost. 30

Ootyjtsign Entope ID. 8808￿2&a02E￿48l￿22l.o30154AIlAol The Lily Foundation Company Limited by Guarantee Notes to the Financial Statements Year ended 31 August 2025 Accoun¢ing poli¢i•s Debtors Other debtors we recognised at the settlement amc¥Jnt due after any trade discount offered. Prepayments are valuad at the amount prepaid after taking account of any trade discounts due. Cash at bank and in hand Cash at bank and cash in hand incbJdes cash and shc¥t tefm hohly liquid rnvestments ¥￿th a short matuity of three rrK>nths or ￿sS from the date of acq￿$111￿ or opening of the depos11 or milar account. Curyent as$¢t invtstments Current asset investments include Cash on deposit wrth a maturity of less than one year held investment purposes rather than to meet short-terni cash commitments as Ihey lall due. Cr¢dltors and provlslon$ Creditors and Provi￿onS are rewnised whare the charrty has a presént Obligati￿ resuking from past event that will probably result in the Iransfer of furK15 to a Ihird party and the amounl due lo Selt￿ the obligation Can be rneasured or ests"mat8d reliabty. Creilitors and provisions are nomally ￿CogniSed at their setuemenl amount after all¢y•ving for any irade discounts due. D•fJn•d eOb)trlbutlon plan$ Contributions to defu)ed conth"trAJts"on plans are re￿￿1￿ as an expense in tho period in whi¢h the related service 15 provided. Dffterences between ￿tn￿AtiOnS payable in the year and the contributions actually pai¢J are shown as either a¢¢wal$ or prepayments on the balance sheet. 31

DocU￿9Th En¥doFQ 10.. 8808LTh)2>802E-8481-82214130IW1 IA01 The Lily Foundation Company Limited by Guarantee Notes to the Financial Statements Year ended 31 August 2025 Llmlt•d by guarantee The charity is incorp(ated under thè Ctnpani•s Act and is limrted by guarantee, each member having undertaken to ¢onthbute such am(xJnts. rb￿ exceeding one pound. as may be required in the event of the conwany being wound up whilst hè of she is st￿1 a mémber or wrthin one year thereafter. There are 9 members ofthe C￿mPanY12024- 9 members). Donations and lega¢i¢s Unrestricted Funds Restricted Total Funds Funds 2025 Other donations and le9aeies Donalions & Sponsorship 717,877 236,169 954,046 Unrestricted Funds Restricted Totsl Fund5 Fund$ 2024 Other donations and lega¢i•s Donalions & Sponsorship 688.332 81.618 769.948 (Xh¢r trading activiti9$ Unrestrictèd Total Fund$ Unrèstricted Total Funds Funds 2025 Funds 2024 Acts'Vrt￿ fr* generating funds 99.881 99.881 176,394 176,394 Investment income Unrestricbj Total Funds Unrestricled T¢Xal Fund5 Funds 2025 Funds 2024 Investment income 40.088 40.088 28.047 28.047 Costs of ralslng donations and l•gxles Unrestricted Total Funds Unr8Stricted Tclal Funds Funds 2025 Funds 2024 Costs of raising donations and legaaes - Donalions 216,￿3 216.563 162.047 162,047 32

Do￿$#Jn En￿lope ITr. B8D8Oo2MD2E4481-8221-￿l34A1lAOl The Lily Foundation Company Limited by Guarantee Notes to the Financial Statements (tth> Year ended 31 August 2025 Costs of oth•r trading acli¥r unrestn.cted Total Funds Unrestricted Total Funds Funds 2025 Funds 2024 Costs of other trading a￿l¥l￿"e$ 89,991 89.991 218,887 218,887 10. Expendlture on ¢harltable aclivities by fund type Unrestricted Funds Restricted Total Funds Fund5 2025 Rvoearch Ex￿dIlure Patient & Famity Support Awareness & Edijcation Support costs 67,441 287.531 1 $5,995 56.386 91,307 80.778 158,748 368.309 189,843 56.386 567,353 205.933 773,286 Unrestricted Funds Restricted Total Funds Funds 2024 Research Expenditure Patient & Family Suppcwt Awaren8ss & Educafion Support costs 221.911 354.187 163.271 116.652 142.847 34.273 364,758 388.460 183,271 116.652 856.021 177.120 1.033,141 33

En¥dope10.' 88D8002>802E-84814221.0>)134A11AO1 The Lily Foundation Company Limited by Guarantee Notes to the Financial Statements (¢&7#oued) Year ended 31 August 2025 11. Expenditure on ¢haritabk actlvities by acti¥rty ty Activilies undertaken Grant tunding dire¢Uy of activities Supwt Total funds 2025 Total fvnd 2024 Research Expendilure Patienl & Fami Support Awareness & Education Govemanc& costs 66.827 91.921 3.991 162.739 376,0￿j 368.309 5.799 374.108 412,414 189.843 12,750 33.846 202,593 33,846 189,111 55,526 624.979 91.921 56,386 773.286 1.033,141 A breakijxn of govemance costs is as folm.. 2025 2024 Audit Fee Oepreciation Legal and yofessional Insurance Freelance costs Salaries Meetings HR Other governance costs 8.744 2,086 3.095 3.036 5.501 8.224 2.187 312 661 6.180 1.935 1.372 1,484 11,029 10.443 6.957 1S,592 534 33.846 55,526 34

DotLnÉrAkyio.. èlo¥J2￿￿E4lB•41ll4DJlJ￿ll￿￿ The Lily Foundation Company Llmlt•d by Gua￿￿1•¢ Notss to the Fin•nclal Statements(￿￿￿￿ Y¢•r ended 31 August 2025 11 At)Atysl olwpportcosts **s SLVW & Eth￿at￿ GMmArte Toi•l 202$ 2024 Commun￿￿￿5 rr Genefaloff Finance cosis Governanc¢ llos PR &ll￿rkthng 3.121 337 4,839 675 4.176 16.640 1.541 303 33.846 11,530 .580 227 S5.526 14.326 33,846 8.574 2.607 4.e67 3.991 5.799 12.750 33.yfj 63.880 141.3DS

DooJsHJn Enve￿￿ ID.. 8908￿2￿￿2E448l￿221-03o134AljAOl The Lily Foundation Company Limited by Guarantee Notes to tho Financial Statements Year ended 31 August 2025 13. Analysi$ 01 grants 2025 2024 Grants to institutiQllS University College London Newcastle University Northumbria University Carnbridge University Rare Disease Research Partners 134.583 12.639 94,315 32,130 23.000 68.921 91.921 273,667 Totsl grants 91.921 273.667 During the current and prior year. the grants supported researth. 14. Net Inc¢>m•ll•xp•ndlture) Net incomèl(expenditure) is stated after chargin￿(c￿dttsngj.' 2025 2024 Depreciation of tangible fixed assets Operatyng lease ￿ntalS 2,087 11,725 1,935 8,736 Fees Payab￿ lo the audrtor were as folk)ws'. 2025 2024 Audit Accwnting Corporation tax compiwnce 8,744 978 1.230 6,180 930 15. Parti¢ulars of employees The totsl staff costs and employee benefits for the rebykn.ng period a￿ anatysed a5 fc41ows'. 2025 2024 Wages and salaries Social secuiity cosls Employer contributi￿$ to pert￿0n plans 466,939 41.847 9,679 451.424 40,257 13,958 518,465 SOS,639 36

Oowstgn En¥eknFe ID." B80BLh)23402E-8481-82214)30134A11AOI The Lily Foundation Company Llmlted by Guarantee Notes to the Financial Statements Year ended 31 August 2025 15. Parti¢ulars of •mploye•s ic*)nrfnuédJ Thè average hèad ￿nt of èmployees during the year was 14 (2024: 13). The avera￿ number of fiJll-time equivalent employees during Ihe year Trs anatyseil as fdlNs.' 2025 2024 No. Inanagement Oiher staff 10 10 The nunthr of empknyees whose remunerati￿ for the year fell wilhin the fdlowing bands, were.. 2025 2024 No. No. £60,000 to £69.999 £70.000 to £79,999 Key Management Pewjnnol Key management personnel include all persons thal have authority and responsibility for planning. directing and controlling the activrtie5 01 ihe company. The total ¢ompensatTrtin paid to key management personnel for service5 provided io Ihe company was £149,373 12024:£188.774}. 16. Trustee remun•ration and expeft$¢s No remuneration was paid to the trustees during the curffjnt ty ￿￿Or year. One trustee receNed reimbursement of expenses in respe¢t of travel totalling £1.23412024.' £nll. 17. Tangible fix￿ assets Fixiures and fiitings Equipment Total Cost Al 1 September 2024 Addrtions 10.729 753 11.013 753 At 31 August 2025 Depreciation At 1 Septémbef 2024 Charge for the year At 31 August2025 Carrying arnount At 31 August 2025 At 31 August 2024 11.482 11.766 284 7.973 2.087 8,257 2,087 284 10.060 10.344 1.422 1.422 2,756 2,756 37

Docu6thJn Enwelope ID." B8D8002>802E4481-8221-OX1134A11AOI The Lily Foundation Company Limited by Guarantee Noles to the Financial Statements {contirnKdJ Year ended 31 August 2025 18. Debtors . 2025 2024 Prepayments ant1 accrued inci Other debtors 94,352 37.012 67.886 131.364 67.886 19. Inv•stments 2025 2024 Short temi dèpti*ts 155,( 20. cr￿ltOrs. amounts falling due within on• y￿r 2025 2024 Trade creditors Accruals and deferred income Social security and other taxes Funds held agents Grant commitments Other creditors 1.409 47.962 15.118 62.660 278.093 7.300 10,892 48.553 12,421 33.392 339,511 412.542 444,769 38

Docusign Envelope ID. B8D8002>802E•81.82214130134A1 IA01 The Lily Foundation Company Limited by Guarantee Notes to the Financial Staternents (¢tyue Year ended 31 August 2025 20. Creditors: amounts falling du¢ wl¢hin on¢ ytsar (¢onll Within 'accruals and deferTed income. there is an amount of £23.767 of deferred income {2024." £27.7161 which relates to income received in advance for fundraising events taking place in the next financial year. Deferred income of £27,716 12024.. £19.3941 was reased Ihe ye￿. Income of £23,76712024". £27.7161%￿S ¢Jeferred during the year. The charty receNed funds held as agent in its rde in administwing research grants in partnership with other funders. The ¢harity wetved lunds of £209.798 12024." £137,352) and made payments of £180.53012024'. £103.9601 leaving a creditor of £62.660 at 31 August 2025 12024.. £33,392) Movemenl in grant commrtments is stated in the tab￿ bel¢x: 2025 2024 Grant commitm￿ts at the start ol th• y•ar New grant commitments charged to the SOFA in the year Grants paid during the year Amount of grant commitments at the end of the ye 515,303 432.053 91.921 273.667 {325,0771 1190,4171 282.147 515.303 2025 2024 Amounts falling due within one year Amounts falling due after one year Anw)unt of grant commitments al the erKI of the year 278,093 4,054 339,511 175,792 282.147 515.303 21. Créditors: amounts falling du• after mor• than one y￿r 2025 2024 Grant commitments 4.054 175,792 22. Pensions and other po$t r¢tir¢m•nt ￿n•￿$ Defined contributiDn plans The amount recognised in income or expenditure as an eX￿lSe in relalion to defined contribution plans was £9.679 {2024." £13,958). 39

DO￿$19n ID". 8808002>802E-84B1-8221-030134A11A01 The Lily Foundation Company Limited by Guarantee Notes to the Financial Statements ic&7*Th1• Year ended 31 August 2025 23. Analysis of charitable fvnds Unrestrict•d funds At 31 August 2025 1 September 2024 IrKthne Expenditure Translers General funds Designated Funds 394.527 gJ4,874 857.846 1873.907) 72,422 172,4221 450,888 432,452 899.401 857.846 1873.907) 83.340 At 31 August 2024 1 Seplember 2023 Expwditu Transfers General funds Designated Funds 660.027 583,556 892,773 {1.236,955} 78,682 178.6821 394,527 504,874 1,243,583 892,773 11.236.955) 899.401 The charity had the fr￿lOW1n9 designated fvnds". 2025 2024 Research Support Awareness Charity Vanable Costs 100,000 220,155 82.656 29,641 92,480 273,094 102,531 36,769 432.452 504.874 Rèstriet•d ￿ndS At 1 SePt￿bar 2024 At 31 August 2025 Ir￿orne Expendrture Transfers Restrirled Funds 41.110 236,169 1205,9331 71,346 At 31 August 2024 1 Seplember Inc(The Expenditure Transfers Restricted Funds 136.614 81.616 1177.120) 41.110

Do￿819Th EDvelJpe ID-. B8DaC¥)Z>&)2E44B14221-030134A11A01 The Lily Foundation Company Limited by Guarantee Notes to the Financial Slalemonts Year ended 31 August 2025 23. Analysis of charitable funds Ouring the year restricted donations and grants tolalling Q36.169 (2024.. £81.6161 were received frMI private donors and compan who wish lo remain anonymous. £124.426 was restricted lo medical research pfojects {2024'. £79.211). £91.307 was spent on these proje¢ts during the year 12024: £142.8471 and £59.247 VAS ￿Me0 f0Th￿rd 12024.. £26.128}. £77,895 was restn"¢ted to pakn.ent support Serv￿ (2024.. £2.4051, £80,778 was spent on these services during the year {2024'. £34,273) and £12,099 was ￿led foThvard {2024'. £14,982). £33,848 was restricted to awareness12024'. £nAI. £33.848 was Spent during the year12024'. £nill and £nil was carned forward12024". £nill. 24. Analysls of net assets betw•en funds Unrestricted Funds Restricted Total Funds Funds 2025 Tangible fixed assets Current Assets Creditors less than 1 year Creditors giealer than 1 year 1,422 1,264,866 1378.8941 {4,0541 1,422 104,994 1.369,860 133,6481 1412,5421 14,0541 Net assets 883,340 71,346 954,686 Unr8$lrcted Funds Restricted Tolal Funds Funds 2024 Tangible fixed assels Current Assets Creditors less than 1 year Creditors greater than 1 year Ntt assets 2.756 1.517.206 1444,769} 1175.792} 899,401 2.756 1.558.316 1444,7691 1175,7921 940,511 41.110 41.110 25. Anatysis of changes ID net debt At 1 Sep 2024 Cash Ilows 31 Aug 2025 Cash at bank and in harKI 1.490.430 (406,934) 1.083,496 41

Docusmjn Envelwe ID.. BBoeD]23-BO2E44814221-1)30134A11A01 The Lily Foundation Company Limited by Guarantee Notes to the Financial Statements Year ended 31 August 2025 26. Related ￿rtIeS Key management pers￿n￿ reM￿￿ation has b88n disdosed in ￿te 15. During the year, Pinder Reaux & Associates Ltd. a c¢Mnpany in which R Bains and J Spyrou have an interest, provided ￿9•1 seNi¢es to the ¢harity as a gffl in kirKI of £9.54712024". £7,237}. No other transactions with related parties were undertaken such as are requ￿e￿ to be disclosed under Ihe Statement of Recommèndèd Praclice lor accounting and reporting by charities. applicab￿ to charities p￿paring their accounts in aecL¥dance with the Financial Reporting Standard applicable in Ihe UK aThJ Republi¢ of Ireland {FRS 1021. 42